Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

Active, not recruiting

Conditions: Glycogen Storage Disease Type II

Interventions: Drug: Alglucosidase alfa GZ419829

First Posted Date: 2021-04-19

Last Posted Date: 2025-05-13

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT04848779

Locations: 🇨🇳
Investigational Site Number : 1580001, Taipei City, Taiwan
🇺🇸
Advanced Medical Genetics- Site Number : 8400002, Hawthorne, New York, United States
🇺🇸
Duke University Medical Center- Site Number : 8400004, Durham, North Carolina, United States

and more 12 locations

A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen

Recruiting

Conditions: Acid SphingoMyelinase Deficiency
Gaucher Disease, Splenomegaly

First Posted Date: 2021-04-15

Last Posted Date: 2024-10-10

Lead Sponsor: Sanofi

Target Recruit Count: 150

Registration Number: NCT04845958

Locations: 🇫🇷
Investigational Site Number 2500034, Argenteuil, France
🇫🇷
Investigational Site Number 2500036, Amiens, France
🇫🇷
Investigational Site Number 2500014, Angers, France

and more 37 locations

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Phase 4

Completed

Conditions: Dermatitis Atopic

Interventions: Drug: Dupilumab (SAR231893)

First Posted Date: 2021-03-30

Last Posted Date: 2023-07-11

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT04823130

Locations: 🇺🇸
Investigational Site Number 8400001, Miami, Florida, United States
🇺🇸
Investigational Site Number 8400002, East Windsor, New Jersey, United States
🇩🇪
Investigational Site Number 2760001, Münster, Germany

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Phase 2

Completed

Conditions: Cutaneous Lupus Erythematosus

Interventions: Drug: SAR443122
Drug: Placebo

First Posted Date: 2021-03-04

Last Posted Date: 2024-06-24

Lead Sponsor: Sanofi

Target Recruit Count: 78

Registration Number: NCT04781816

Locations: 🇮🇳
Investigational Site Number : 3560002, Chandigarh, India
🇲🇽
Investigational Site Number : 4840002, Veracruz, Mexico
🇺🇸
ClinOhio Research Services Site Number : 8400007, Columbus, Ohio, United States

and more 47 locations

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Itepekimab SAR440340
Drug: Placebo

First Posted Date: 2021-02-12

Last Posted Date: 2024-07-12

Lead Sponsor: Sanofi

Target Recruit Count: 1210

Registration Number: NCT04751487

Locations: 🇺🇸
Temple University Hospital Site Number : 8400062, Philadelphia, Pennsylvania, United States
🇺🇸
Remington-Davis Inc Site Number : 8400004, Columbus, Ohio, United States
🇺🇸
Care Access Site Number : 8400276, Boston, Massachusetts, United States

and more 314 locations

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasm
Cancer

Interventions: Drug: SAR444881
Drug: Pembrolizumab
Drug: Cetuximab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2021-01-22

Last Posted Date: 2025-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 456

Registration Number: NCT04717375

Locations: 🇮🇱
Investigational Site Number : 3760005, Jerusalem, Israel
🇮🇱
Investigational Site Number : 3760001, Petah Tikva, Israel
🇮🇱
Investigational Site Number : 3760003, Ramat Gan, Israel

and more 15 locations

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

Phase 4

Completed

Conditions: Dermatitis Atopic

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2021-01-22

Last Posted Date: 2023-10-17

Lead Sponsor: Sanofi

Target Recruit Count: 41

Registration Number: NCT04718870

Locations: 🇬🇧
Investigational Site Number :8260001, Sheffield, United Kingdom
🇺🇸
Investigational Site Number :8400002, Los Angeles, California, United States
🇺🇸
Investigational Site Number :8400001, Denver, Colorado, United States

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

Phase 3

Terminated

Conditions: Congenital Cystic Kidney Disease

Interventions: Drug: Venglustat GZ402671

First Posted Date: 2021-01-12

Last Posted Date: 2022-10-06

Lead Sponsor: Sanofi

Target Recruit Count: 24

Registration Number: NCT04705051

Locations: 🇳🇱
Investigational Site Number :5280002, Nijmegen, Netherlands
🇯🇵
Investigational Site Number :3920007, Osaka-shi, Osaka, Japan
🇯🇵
Investigational Site Number :3920002, Bunkyo-ku, Tokyo, Japan

and more 8 locations

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Itepekimab SAR440340
Drug: Placebo

First Posted Date: 2021-01-08

Last Posted Date: 2024-07-12

Lead Sponsor: Sanofi

Target Recruit Count: 960

Registration Number: NCT04701983

Locations: 🇺🇸
MACRO Trials Site Number : 8400030, Los Angeles, California, United States
🇺🇸
Covenant Pulmonary Critical Care Site Number : 8400183, Atlanta, Georgia, United States
🇺🇸
Clinical Research of Central PA Site Number : 8400023, DuBois, Pennsylvania, United States

and more 245 locations

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

Phase 3

Completed

Conditions: Allergic Fungal Rhinosinusitis

Interventions: Drug: Placebo
Drug: Dupilumab SAR231893

First Posted Date: 2020-12-24

Last Posted Date: 2025-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 62

Registration Number: NCT04684524

Locations: 🇸🇦
Investigational Site Number : 6820001, Riyadh, Saudi Arabia
🇹🇷
Investigational Site Number : 7920007, Istanbul, Turkey
🇦🇷
Investigational Site Number : 0320004, Mendoza, Argentina

and more 44 locations

Home Terms & Conditions Privacy Policy